17 August 2025 : Clinical Research
Evaluation of Inflammatory Biomarkers in Parotid Tumors
Aykut Ikinciogullari
ABCDEF 1*, Burak Hazir ABCDEF 1, Erdem Aggunlu ABCDEF 1, Mustafa Colak ACDEF 1, Serdar Ensari ADEF 1, Haci Huseyin Dere ADEF 1
DOI: 10.12659/MSM.947334
Med Sci Monit 2025; 31:e947334
Table 4 Inflammatory biomarkers NLR, PLR, SII, and SIRI across benign, low-grade malignant, and high-grade malignant tumors.
| NLR (mean±SD, median) | PLR (mean±SD, median) | SII (mean±SD, median) | SIRI (mean±SD, median) | |
|---|---|---|---|---|
| Benign | 2.24±0.96, 2.04 | 119.64±40.81, 112.90 | 562.34±250.64, 506.10 | 1.06±0.62, 0.91 |
| Low grade malignant | 2.28±0.78, 2.04 | 121.19±37.04, 118.24 | 577.91±190.24, 519.92 | 1.05±0.6, 1.06 |
| High grade malignant | 3.07±2.61, 2.34 | 155.12±52.04, 143.79 | 1092.70±1167.25, 802.32 | 2.18±4.09, 0.95 |
| value* | 0.519 | 0.05** | 0.07 | 0.803 |
| * Kruskal-Wallis test; ** statistically significant. NLR – neutrophil to lymphocyte ratio; PLR – platelet-to-lymphocyte ratio; SII – systemic immune inflammation index; SIRI – systemic inflammation response index. | ||||